Response and Resistance to Trametinib in MAP2K1-Mutant Triple-Negative Melanoma.

Details

Ressource 1Download: ijms-24-04520-v3.pdf (4234.15 [Ko])
State: Public
Version: Final published version
License: CC BY 4.0
Serval ID
serval:BIB_E3A48A3138B7
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Response and Resistance to Trametinib in MAP2K1-Mutant Triple-Negative Melanoma.
Journal
International journal of molecular sciences
Author(s)
Krebs F.S., Moura B., Missiaglia E., Aedo-Lopez V., Michielin O., Tsantoulis P., Bisig B., Trimech M., Zoete V., Homicsko K.
ISSN
1422-0067 (Electronic)
ISSN-L
1422-0067
Publication state
Published
Issued date
24/02/2023
Peer-reviewed
Oui
Volume
24
Number
5
Pages
4520
Language
english
Notes
Publication types: Case Reports
Publication Status: epublish
Abstract
The development of targeted therapies for non-BRAF p.Val600-mutant melanomas remains a challenge. Triple wildtype (TWT) melanomas that lack mutations in BRAF, NRAS, or NF1 form 10% of human melanomas and are heterogeneous in their genomic drivers. MAP2K1 mutations are enriched in BRAF-mutant melanoma and function as an innate or adaptive resistance mechanism to BRAF inhibition. Here we report the case of a patient with TWT melanoma with a bona fide MAP2K1 mutation without any BRAF mutations. We performed a structural analysis to validate that the MEK inhibitor trametinib could block this mutation. Although the patient initially responded to trametinib, he eventually progressed. The presence of a CDKN2A deletion prompted us to combine a CDK4/6 inhibitor, palbociclib, with trametinib but without clinical benefit. Genomic analysis at progression showed multiple novel copy number alterations. Our case illustrates the challenges of combining MEK1 and CDK4/6 inhibitors in case of resistance to MEK inhibitor monotherapy.
Keywords
Male, Humans, Skin Neoplasms/genetics, Melanoma/genetics, Pyridones/therapeutic use, Pyrimidinones/therapeutic use, Protein Kinase Inhibitors/pharmacology, Mitogen-Activated Protein Kinase Kinases/genetics, Proto-Oncogene Proteins B-raf/genetics, Mutation, MAP Kinase Kinase 1/genetics, MAP2K1, cancer, modelling, mutation, triple-negative melanoma
Pubmed
Web of science
Open Access
Yes
Create date
01/03/2023 13:57
Last modification date
15/12/2023 7:53
Usage data